Synergy of nitric oxide and azoles against Candida species in vitro

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 9, 1998, Pages 2342-2346

  McElhaney Feser, Gail E ^a   Raulli, Robert E ^b   Cihlar, Ronald L ^a  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Amulet Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,3 BIS(2 AMINOETHYL) 1 HYDROXY 2 OXOTRIAZENE; FLUCONAZOLE; KETOCONAZOLE; MICONAZOLE; NITRIC OXIDE; PYRROLE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIMICROBIAL ACTIVITY; ARTICLE; CANDIDA; COMPLEX FORMATION; DRUG ACTIVITY; DRUG POTENTIATION; DRUG SENSITIVITY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

EID: 0031684610     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.9.2342     Document Type: Article

References (33)

1. Brenman, J. E., and D. S. Bredt. 1996. Nitric oxide signaling in the nervous system. Methods Enzymol. 269:119-128.
2. Chin, N.-X., I. Weitzman, and P. Della-Latta. 1997. In vitro activity of fluvastatin, a cholesterol-lowering agent, and synergy with fluconazole and itraconazole against Candida species and Cryptococcus neoformans. Antimicrob. Agents Chemother. 41:850-852.
3. De Groote, M. A., and F. C. Fang. 1995. NO inhibitions: antimicrobial properties of nitric oxide. Clin. Infect. Dis. 21(Suppl. 2):S162-S165.
4. Dermoumi, H. 1994. In vitro susceptibility of fungal isolates of clinically important specimens to itraconazole, fluconazole and amphotericin B. Chemotherapy 40:92-98.
5. Draso, R. S. 1962. Reactions of nitrogen (II) oxide, free radicals in organic chemistry. Advances in chemistry series, no. 36. American Chemical Society, Washington, D.C.
6. Drapier, J.-C., and J. B. Hibbs, Jr. 1996. Aconitase: a class of metalloproteins highly sensitive to nitric oxide synthesis. Methods Enzymol. 269:26-36.
7. Ducan, C., D. Hamish, P. Johnston, S. Green, R. Brogan, C. Leifert, L. Smith M. Golden, and N. Benjamin. 1995. Chemical generation of nitric oxide in the mouth from the enterosalivary circulation of dietary nitrate. Nat. Med. 1:146-151.
8. Farias-Eisner, R., G. Chaudhuri, E. Aeberhard, and J. M. Fukuto. 1996. The chemistry and tumoricidal activity of nitric oxide/hydrogen peroxide and the implications to cell resistance/susceptibility. J. Biol. Chem. 271:6144-6151.
9. Galgiani, J. N., and M. L. Lewis. 1997. In vitro studies of the activities of the antifungal triazoles SCH56592 and itraconazole against Candida albicans. Cryptococcus neoformans, and other pathogenic yeasts. Antimicrob. Agents Chemother. 41:180-183.
10. Granger, D. N., and P. Kubes. Nitric oxide as antiinflammatory agent. Methods Enzymol. 269:434-441.
11. Hibbs, J. B., Jr., R. R. Taintor, Z. Vavrin, and E. M. Rachlin. 1988. Nitric oxide: a cytotoxic activated macrophage effector molecule. Biochem. Biophys Res. Commun. 157:87-94.
12. Hrabie, J. A., J. R. Klose, D. A. Wink, and L. K. Keefer. 1993. New nitric oxide-releasing zwitterions derived from polyamines. J. Org. Chem. 58:1472-1476.
13. Jones-Carson, J., A. Vazquez-Torres, H. C. Van Der Heyde, T. Warner, R. D. Wagner, and E. Balish. 1995. γδ T cell-induced nitric oxide production enhances resistance to mucosal candidiasis. Nat. Med. 1:552-557.
14. Keefer, L. K., R. W. Nims, K. W. Davies, and D. K. Wink. 1996. "NONOates" (1-substituted diazen-1-ium-1,2-diolates) as nitric oxide donors: convenient nitric oxide dosage forms. Methods Enzymol. 268:281-293.
15. Manning, M., and T. G. Mitchell. 1980. Strain variations and morphogenesis of yeast and mycelial-phase Candida albicans in low sulfate, synthetic medium. J. Bacteriol. 142:714-719.
16. Maragos, C. M., D. Morley, D. A. Wink, T. M. Dunams J. E. Saavedra, A. Hoffman, A. A. Bove, L. Isaac, J. A. Harbie, and L. K. Keefer. 1991. Complexes of NO with nucleophiles as agents for the controlled biological release of nitric oxide. Vasorelaxant effects. J. Med. Chem. 34:3242-3247.
17. Moncada, S., R. M. J. Palmer, and E. A. Higgs. 1991. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol. Rev. 43:109-142.
18. Mooradian, D. L., T. C. Hutsell, and L. K. Keefer. 1995. Nitric oxide (NO donor molecules: effect of NO release rate on vascular smooth muscle cell proliferation in vitro. J. Cardiovasc. Pharmacol. 25:674-678.
19. Moran, G. P., D. J. Sullivan, M. C. Henman, C. E. McCreary, B. J. Harrington, D. B. Shanley, and D. C. Coleman. 1997. Antifungal drug susceptibilities of oral Candida dubliniensis isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected subjects and generation of stable fluconazole-resistant derivatives in vitro. Antimicrob. Agents Chemother. 41:617-623
20. National Committee for Clinical Laboratory Standards. 1995. Reference method for broth dilution antifungal susceptibility testing of yeasts. Tentative standards. NCCLS document M27-T, vol. 15, no. 10. National Committee for Laboratory Standards, Wayne, Pa.
21. Odds, F. C. 1993. Resistance of yeasts to azole-derivative antifungals. J. Antimicrob. Chemother. 31:463-471.
22. Odds, F. C., and R. Bernaerts. 1994. CHROMagar Candida, a new differential isolation medium for presumptive identification of clinically important Candida species. J. Clin. Microbiol. 32:1923-1929.
23. Pfaller, M. A., S. Messer, and R. N. Jones. 1997. Activity of a new triazole, Sch 16592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae. Antimicrob. Agents Chemother. 41:233-235.
24. Raulli, R. E. 1998. Inhibition of platelet aggregation in man by diazenium-diolates: extent of inhibition correlates with nitric oxide load delivered. J. Pharm. Pharmacol. 50:1-8.
25. Saavedra, J. E., T. R. Billiar, D. L. Williams, Y.-M. Kim, S. C. Watkins, and L. K. Keefer. 1997. Targeting nitric oxide (NO) delivery in vitro. Design of a liver-selective NO donor prodrug that blocks tumor necrosis factor-α-induced apoptosis and toxicity in the liver. J. Med. Chem. 40:1947-1954.
26. Sanglard, D., K. Kuchler, F. Ischer, J.-L. Pagani, M. Monod, and J. Bille. 1995 Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob. Agents Chemother. 39:2378-2386.
27. Scott, E. M., V. N. Tariq, and R. M. McCrory. 1995. Demonstration of synergy with fluconazole and either ibuprofen, sodium salicylate, or propylparaben against Candida albicans in vitro. Antimicrob. Agents Chemother. 39:2610-2614.
28. Stamler, J. S., D. J. Singel, and J. Loscalzo. 1992. Biochemistry of nitric oxide and its redox-activated forms. Science 258:1898-1902.
29. Stuehr, D. J., and C. F. Nathan. 1977. Nitric oxide: a macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. J. Exp. Med. 169:1543-1555.
30. Tamir, S., T. DeRojas-Walker, J. S. Wishnok, and S. R. Tannenbaum. 1996. DNA damage and genotoxicity by nitric oxide. Methods Enzymol. 269:230-943.
31. Vanden Bossche, H., D. W. Warnock, B. Dupont, D. Kerridge, S. Sen Gupta, L. Improvisi, P. Marichal, F. C. Odds, F. Provost, and O. Ronin. 1994. Mechanisms and clinical impact of antifungal drug resistance. J. Med. Vet. Mycol. 32(Suppl. 1):189-202.
32. Vazquez, J. A., M. Lynch, and J. D. Sobel. 1995. In vitro activity of a new pneumocandin antifungal agent, L-733,560, against azole-susceptible and -resistant Candida and Torulopsis species. Antimicrob. Agents Chemother. 39:2689-2691
33. Walsh, T., J., J. Peter, D. A. McGough, A. W. Fothergill, M. G. Rinaldi, and P. A. Pizzo 1995 Activities of amphotericin B and antifungal azoles alone and in combination against Pseudallescheria boydii. Antimicrob. Agents Chemother. 39:1361-1364.